©2022 Stanford Medicine
Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
Not Recruiting
Trial ID: NCT00350142
Purpose
This study will assess the efficacy of treating locally advanced pancreatic cancer using
Stereotactic Body Radiotherapy (using Trilogy) and Gemcitabine
Official Title
Phase II Study to Evaluate the Efficacy of Trilogy Stereotactic Radiosurgery for Pancreatic Cancer
Stanford Investigator(s)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:- Pancreatic tumors not to exceed 10 cm in greatest axial dimension
- Histologically confirmed malignancies of the pancreas
- Unresectable by CT criteria or exploratory laparotomy or laparoscopy
- Patients with metastatic disease may be treated if they are symptomatic from the
primary tumor
- Performance status of 0, 1, or 2
- No chemotherapy two weeks prior or two weeks following radiosurgery
Exclusion Criteria:
- patients who have had prior radiotherapy to upper abdomen
- patients receiving any prior pancreatic cancer therapy
- children, pregnant, and breastfeeding women, and lab personnel are excluded
- uncontrolled intercurrent illnesses
- any concurrent malignancy
Intervention(s):
other: 4D pancreatic protocol CT scan
radiation: FDG PET scan
radiation: Stereotactic Body Radiotherapy
drug: Gemcitabine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jeff Kim
6504987703